BCTXW (BriaCell Therapeutics) Beginning Cash Position: $29.90 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BCTXW BriaCell Therapeutics Corp BCTXW
27 GF Score
Price $0.00
! 2 Warning Signs
View Full Analysis

What is BriaCell Therapeutics Beginning Cash Position?

BriaCell Therapeutics BCTXW 27 Beginning Cash Position is $29.90 Mil as of Apr. 2026. GuruFocus rates BCTXW with a GF Score™ of 27/100. The stock has 2 warning signs investors should review.

BriaCell Therapeutics's Beginning Cash Position for the quarter that ended in Apr. 2026 was $29.90 Mil.

BriaCell Therapeutics's quarterly Beginning Cash Position declined from Oct. 2025 ($10.49 Mil) to Jan. 2026 ($2.72 Mil) but then increased from Jan. 2026 ($2.72 Mil) to Apr. 2026 ($29.90 Mil).

BriaCell Therapeutics's annual Beginning Cash Position declined from Jul. 2023 ($41.04 Mil) to Jul. 2024 ($21.25 Mil) and declined from Jul. 2024 ($21.25 Mil) to Jul. 2025 ($0.86 Mil).

BriaCell Therapeutics Beginning Cash Position Related Terms

BriaCell Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for BriaCell Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BriaCell Therapeutics Beginning Cash Position Chart

BriaCell Therapeutics Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 57.27 41.04 21.25 0.86

BriaCell Therapeutics Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.01 12.46 10.49 2.72 29.90
BCTXW
27GF Score
BriaCell Therapeutics Corp BCTXW
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BriaCell Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $29.90 Mil mean?
BriaCell Therapeutics (BCTXW) has a Beginning Cash Position of $29.90 Mil as of Apr. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on BriaCell Therapeutics and its competitors.
Is BriaCell Therapeutics' Beginning Cash Position too high?
BriaCell Therapeutics' current Beginning Cash Position is $29.90 Mil. Overall, BriaCell Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does BriaCell Therapeutics' Beginning Cash Position compare to VRTX and REGN?
BriaCell Therapeutics' Beginning Cash Position of $29.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on BriaCell Therapeutics and its competitors. BriaCell Therapeutics's current Beginning Cash Position is $29.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BriaCell Therapeutics stock overvalued right now?
BriaCell Therapeutics (BCTXW) has a current Beginning Cash Position of $29.90 Mil. The current Beginning Cash Position is $29.90 Mil. BriaCell Therapeutics' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For BriaCell Therapeutics (BCTXW), the current Beginning Cash Position is $29.90 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BriaCell Therapeutics Business Description

Address 235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
27GF Score

Get the complete analysis for BCTXW

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price